PURPOSE: The aims of this trial were to assess the safety and efficacy of two different dosing schedules of irinotecan (CPT-11) in recurrent glioma patients, to assess irinotecan pharmacokinetics in patients on enzyme-inducing antiepileptic drugs (EIAEDs) and steroids, and to correlate with toxicity and response to treatment. METHODS:Sixty-four recurrent glioma patients were included in this study. Schedule A patients received irinotecan weekly (125 mg/m(2)/w) for four out of six weeks. Schedule B patients received irinotecan every three weeks at a dose of 300 mg/m(2). A 20% dose reduction was implemented for patients who had received prior nitrosureas. Treatment was continued until unacceptable toxicity, tumor progression or patient withdrawal. RESULTS: There was no difference in confirmed responses between the two groups (6.3%). PFS at 6 months was 6.25% (2/32 patients) on schedule A and 18.75% (6/32 patients) on schedule B but median OS (5.1 versus 5.5 months), and survival at one year (19%) was similar for both arms. The most common grade 3-4 toxicities on schedules A/B were: thrombocytopenia (15.6%/21.9%), diarrhea (6.3%/12.5%) and nausea and vomiting (0%/15.7%). One toxic death due to infection in the absence of neutropenia occurred in schedule B. EIAEDs reduced SN-38 and CPT-11 area under the curve and increased CPT-11 clearance. This effect was more prominent in schedule A patients. Steroids did not alter CPT-11 pharmacokinetics in either schedule. CONCLUSIONS:Single agent irinotecan has modest activity in patients with recurrent gliomas, independently of the administration schedule. Irinotecan administration on an every 3 week schedule resulted in longer PFS-6, at the expense of more toxicity. EIAEDs alter CPT-11 pharmacokinetics in this group of patients, and should be taken into consideration when determining optimal dosing.
RCT Entities:
PURPOSE: The aims of this trial were to assess the safety and efficacy of two different dosing schedules of irinotecan (CPT-11) in recurrent gliomapatients, to assess irinotecan pharmacokinetics in patients on enzyme-inducing antiepileptic drugs (EIAEDs) and steroids, and to correlate with toxicity and response to treatment. METHODS: Sixty-four recurrent gliomapatients were included in this study. Schedule A patients received irinotecan weekly (125 mg/m(2)/w) for four out of six weeks. Schedule B patients received irinotecan every three weeks at a dose of 300 mg/m(2). A 20% dose reduction was implemented for patients who had received prior nitrosureas. Treatment was continued until unacceptable toxicity, tumor progression or patient withdrawal. RESULTS: There was no difference in confirmed responses between the two groups (6.3%). PFS at 6 months was 6.25% (2/32 patients) on schedule A and 18.75% (6/32 patients) on schedule B but median OS (5.1 versus 5.5 months), and survival at one year (19%) was similar for both arms. The most common grade 3-4 toxicities on schedules A/B were: thrombocytopenia (15.6%/21.9%), diarrhea (6.3%/12.5%) and nausea and vomiting (0%/15.7%). One toxic death due to infection in the absence of neutropenia occurred in schedule B. EIAEDs reduced SN-38 and CPT-11 area under the curve and increased CPT-11 clearance. This effect was more prominent in schedule A patients. Steroids did not alter CPT-11 pharmacokinetics in either schedule. CONCLUSIONS: Single agent irinotecan has modest activity in patients with recurrent gliomas, independently of the administration schedule. Irinotecan administration on an every 3 week schedule resulted in longer PFS-6, at the expense of more toxicity. EIAEDs alter CPT-11 pharmacokinetics in this group of patients, and should be taken into consideration when determining optimal dosing.
Authors: V M Herben; J H Schellens; M Swart; G Gruia; L Vernillet; J H Beijnen; W W ten Bokkel Huinink Journal: J Clin Oncol Date: 1999-06 Impact factor: 44.544
Authors: D F Stefanik; W K Fellows; L R Rizkalla; W M Rizkalla; P P Stefanik; A B Deleo; W C Welch Journal: J Neurooncol Date: 2001-11 Impact factor: 4.130
Authors: H C Pitot; J A Knost; M R Mahoney; J Kugler; J E Krook; A K Hatfield; D J Sargent; R M Goldberg Journal: Cancer Date: 2000-10-15 Impact factor: 6.860
Authors: Timothy F Cloughesy; Emese Filka; Gillian Nelson; Fairooz Kabbinavar; Henry Friedman; Langdon L Miller; Gary L Elfring Journal: Am J Clin Oncol Date: 2002-04 Impact factor: 2.339
Authors: Timothy F Cloughesy; Emese Filka; John Kuhn; Gillian Nelson; Fairooz Kabbinavar; Henry Friedman; Langdon L Miller; Gary L Elfring Journal: Cancer Date: 2003-05-01 Impact factor: 6.860
Authors: Mark R Gilbert; Jeffrey G Supko; Tracy Batchelor; Glenn Lesser; Joy D Fisher; Steven Piantadosi; Stuart Grossman Journal: Clin Cancer Res Date: 2003-08-01 Impact factor: 12.531
Authors: Tracy T Batchelor; Mark R Gilbert; Jeffrey G Supko; Kathryn A Carson; Louis B Nabors; Stuart A Grossman; Glenn J Lesser; Tom Mikkelsen; Surasak Phuphanich Journal: Neuro Oncol Date: 2004-01 Impact factor: 12.300
Authors: Monica E Loghin; Michael D Prados; Patrick Wen; Larry Junck; Frank Lieberman; Howard Fine; Karen L Fink; Minesh Metha; John Kuhn; Kathleen Lamborn; Susan M Chang; Timothy Cloughesy; Lisa M DeAngelis; Ian H Robins; Kenneth D Aldape; W K Alfred Yung Journal: Clin Cancer Res Date: 2007-12-01 Impact factor: 12.531
Authors: Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter Journal: Neuro Oncol Date: 2015-11 Impact factor: 12.300
Authors: Alexander K Berg; Jan C Buckner; Evanthia Galanis; Kurt A Jaeckle; Matthew M Ames; Joel M Reid Journal: J Clin Pharmacol Date: 2015-06-26 Impact factor: 3.126
Authors: David A Reardon; James J Vredenburgh; Annick Desjardins; Katherine Peters; Sridharan Gururangan; John H Sampson; Jennifer Marcello; James E Herndon; Roger E McLendon; Dorothea Janney; Allan H Friedman; Darell D Bigner; Henry S Friedman Journal: J Neurooncol Date: 2010-05-05 Impact factor: 4.130
Authors: Matthew P Goetz; Heidi A McKean; Joel M Reid; Sumithra J Mandrekar; Angelina D Tan; Mary A Kuffel; Stephanie L Safgren; Renee M McGovern; Richard M Goldberg; Axel A Grothey; Robert McWilliams; Charles Erlichman; Matthew M Ames Journal: Invest New Drugs Date: 2013-10-10 Impact factor: 3.850
Authors: David A Reardon; Annick Desjardins; Katherine B Peters; Sridharan Gururangan; John H Sampson; Roger E McLendon; James E Herndon; Anuradha Bulusu; Stevie Threatt; Allan H Friedman; James J Vredenburgh; Henry S Friedman Journal: J Neurooncol Date: 2011-10-11 Impact factor: 4.130
Authors: Kurt A Jaeckle; Karla V Ballman; Caterina Giannini; Paula J Schomberg; Matthew M Ames; Joel M Reid; Renee M McGovern; Stephanie L Safgren; Evanthia Galanis; Joon H Uhm; Paul D Brown; Julie E Hammack; Robert Arusell; Daniel A Nikcevich; Roscoe F Morton; Donald B Wender; Jan C Buckner Journal: J Neurooncol Date: 2010-01-09 Impact factor: 4.130